The Trip of a Lifetime
DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A Mark your calendar – DOSED
July 6, 2022
DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A Mark your calendar – DOSED
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment
Novamind Partner to Acquire Specialized Ibogaine Group in Brazil Bienstar plans to build LATAM’s first
Ibogaine blocks some of the rewarding effects of alcohol in rodent model of addictive behavior
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program Tripping on ibogaine can last over
Universal Ibogaine Signs Memorandum Of Understanding With Osoyoos Indian Band Calgary, AB – February 10,
Universal Ibogaine Commences Development Plan At Kelburn In Preparation For Ibogaine Treatments And Provides Update
Universal Ibogaine Enters Drug Supply Agreement Calgary, AB – January 26, 2022 – Universal Ibogaine
Universal Ibogaine Announces World-class Clinical Trial Partners In Advance Of Clinical Trial Application For Ibogaine
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC MindMed (MNMD) developed a non-hallucinogenic molecule
Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on
‘Magic’ Mushrooms, Ecstasy, Other Psychedelics Could Become Legal in California Marcus Capone, a former Navy
MINDCURE Provides Update on Studies and Clinical Trials VANCOUVER, BC, Nov. 4, 2021 /CNW/ – Mind
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics Completing IND-enabling studies with
Congress to Vote on Psychedelics Research Amendments for Active Military Members The US government is
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder